Model favours more personalised screening for prostate cancer

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f711 (Published 6 February 2013)
Cite this as: BMJ 2013;346:f711

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

OpenUrlMedline

For a long time the debate about screening for prostate cancer has focused on the trade off between potential benefits (lives saved) and harms (overdiagnosis, overtreatment), although quantifying either is proving difficult. …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL